Prothipendyl

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Prothipendyl
Accession Number
DB12958
Type
Small Molecule
Groups
Investigational
Description

Prothipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
5O6VWA87VA
CAS number
303-69-5
Weight
Average: 285.41
Monoisotopic: 285.129968798
Chemical Formula
C16H19N3S
InChI Key
JTTAUPUMOLRVRA-UHFFFAOYSA-N
InChI
InChI=1S/C16H19N3S/c1-18(2)11-6-12-19-13-7-3-4-8-14(13)20-15-9-5-10-17-16(15)19/h3-5,7-10H,6,11-12H2,1-2H3
IUPAC Name
dimethyl(3-{9-thia-2,4-diazatricyclo[8.4.0.0^{3,8}]tetradeca-1(14),3(8),4,6,10,12-hexaen-2-yl}propyl)amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1N=CC=C2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineProthipendyl may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineProthipendyl may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineProthipendyl may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Prothipendyl.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Prothipendyl.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Prothipendyl.Approved
AmphetamineProthipendyl may decrease the stimulatory activities of Amphetamine.Approved, Illicit
BenzphetamineProthipendyl may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prothipendyl.Approved, Investigational
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Prothipendyl.Approved, Investigational
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prothipendyl.Approved
ChlorphentermineProthipendyl may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Prothipendyl.Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prothipendyl.Approved, Vet Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prothipendyl.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Prothipendyl.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prothipendyl.Approved
DextroamphetamineProthipendyl may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prothipendyl.Approved
DiethylpropionProthipendyl may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prothipendyl.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Prothipendyl.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Prothipendyl.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prothipendyl.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prothipendyl.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prothipendyl.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prothipendyl.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Prothipendyl.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prothipendyl.Approved, Illicit, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Prothipendyl.Approved, Vet Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Prothipendyl.Approved, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Prothipendyl.Approved, Investigational
GepefrineProthipendyl may decrease the stimulatory activities of Gepefrine.Experimental
HydroxyamphetamineProthipendyl may decrease the stimulatory activities of Hydroxyamphetamine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Prothipendyl.Approved
Iofetamine I-123Prothipendyl may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prothipendyl.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Prothipendyl.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Prothipendyl.Approved, Investigational
LisdexamfetamineProthipendyl may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Prothipendyl.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Prothipendyl.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prothipendyl.Approved
MephedroneProthipendyl may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineProthipendyl may decrease the stimulatory activities of Mephentermine.Approved
MequitazineProthipendyl may increase the arrhythmogenic activities of Mequitazine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Prothipendyl.Approved
MethamphetamineProthipendyl may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethoxyphenamineProthipendyl may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Methylphenidate.Approved, Investigational
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prothipendyl.Approved, Investigational
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prothipendyl.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Prothipendyl.Approved
MidomafetamineProthipendyl may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Prothipendyl.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Prothipendyl.Approved
MMDAProthipendyl may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prothipendyl.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Prothipendyl.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Prothipendyl.Approved, Withdrawn
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Prothipendyl.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Prothipendyl.Approved, Investigational
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prothipendyl.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prothipendyl.Approved
PhentermineProthipendyl may decrease the stimulatory activities of Phentermine.Approved, Illicit
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Prothipendyl.Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Prothipendyl.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prothipendyl.Approved
PseudoephedrineProthipendyl may decrease the stimulatory activities of Pseudoephedrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Prothipendyl.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prothipendyl.Approved
RitobegronProthipendyl may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Prothipendyl.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prothipendyl.Approved, Investigational, Vet Approved
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Prothipendyl.Approved
SulpirideThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Sulpiride.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Prothipendyl.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Prothipendyl.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prothipendyl.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prothipendyl.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Prothipendyl.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prothipendyl.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Prothipendyl.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prothipendyl.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Prothipendyl.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Prothipendyl.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Prothipendyl.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Prothipendyl.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prothipendyl.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
14670
PubChem Substance
347829098
ChemSpider
14002
ChEBI
135182
ChEMBL
CHEMBL2111030
ATC Codes
N05AX07 — Prothipendyl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.128 mg/mLALOGPS
logP3.53ALOGPS
logP3.31ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity87.11 m3·mol-1ChemAxon
Polarizability32.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Alkyldiarylamines
Alternative Parents
Diarylthioethers / Benzothiazines / Pyridines and derivatives / Imidolactams / Benzenoids / 1,4-thiazines / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Alkyldiarylamine / Diarylthioether / Benzothiazine / Aryl thioether / Para-thiazine / Pyridine / Benzenoid / Imidolactam / Heteroaromatic compound / Tertiary aliphatic amine
show 6 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 19:35 / Updated on December 01, 2017 16:35